טוען...
Visceral Leishmaniasis – Optimum Treatment Options in Children
Visceral leishmaniasis (VL) affects 200-400 thousands people annually worldwide. For last few decades there has been a steady decline in the response to pentavalent antimonial (Sb(v)), the drug that has been used for treating VL for almost a century. Oral miltefosine and amphotericin B are alternati...
שמור ב:
| הוצא לאור ב: | Pediatr Infect Dis J |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5990428/ https://ncbi.nlm.nih.gov/pubmed/29280784 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/INF.0000000000001885 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|